Overview

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Status:
Recruiting

Trial end date:
2024-11-30

Target enrollment:

Participant gender:

Summary

The investigators hypothesize that MGD006 for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with MGD006 will be safe, tolerable and may provide additional therapeutic efficacy.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

MacroGenics
National Cancer Institute (NCI)